<DOC>
	<DOCNO>NCT00003652</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : This randomized phase III trial study different regimen give combination chemotherapy together radiation therapy compare well work treat patient stage II stage III anal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy Treating Patients With Stage II Stage III Anal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy concurrent chemotherapy radiotherapy without neoadjuvant chemotherapy fluorouracil cisplatin patient stage II III anal canal cancer . - Compare efficacy two level radiation dose patient stage II III anal canal cancer . - Compare sphincter conservation anus regimen . - Compare effect regimens survival quality life patient . OUTLINE : This randomize , multicenter study . Patients randomize one four treatment arm . - Arm I : Patients receive induction chemotherapy consist fluorouracil IV 24 hour day 1-4 cisplatin IV 1 hour day 1 2 every 4 week 2 course . Beginning 4 week later , patient receive chemoradiotherapy . This regimen consist fluorouracil IV 24 hour day 1-4 cisplatin IV 1 hour day 1 2 repeat 4 week later , plus pelvic radiotherapy begin day 1 continue 5 week ( day , 5 days/week ) . Patients receive low dose radiotherapy directly tumor begin 3 week later continue 2 week . - Arm II : Patients receive induction chemotherapy chemoradiotherapy arm I , plus high dose radiotherapy directly tumor . - Arm III ( control arm ) : Patients receive chemoradiotherapy low dose radiotherapy tumor arm I . - Arm IV : Patients receive chemoradiotherapy high dose radiotherapy tumor arm II . After study treatment complete , patient nonfixed inguinal tumor may undergo surgical resection follow radiotherapy radiotherapy alone . Patients fixed inguinal tumor may receive radiotherapy alone . Quality life assess treatment , 2 month completion treatment , 5 year . Patients follow every 4 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 350 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven nonmetastatic anal cancer Anal/rectal junction OR Anal/cutaneous junction majority tumor anal canal , junction Epidermoid cancer ( welldifferentiated , fairly differentiate , basaloid ) OR Cloacogenic cancer Stage II III T2 least 4 cm OR T3 OR T4 , N03 , M0 OR T1 , N13 OR T2 ( less 4 cm ) , N13 Tumors least 4 cm great dimension and/or tumor lymph node invasion must nonmetastatic ultrasound No prior surgery remove tumor PATIENT CHARACTERISTICS : Age : 80 Performance status : WHO 0 1 Life expectancy : Not specify Hematopoietic : WBC least 2,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 11 g/dL ( transfusion allow ) Hepatic : Not specify Renal : Creatinine great 1.5 mg/dL Cardiovascular : No cardiac condition contraindicate use fluorouracil Other : No prior malignancy within 5 year except squamous cell basal cell skin cancer carcinoma situ cervix breast No serious medical psychological condition No serious immunosuppression PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy Chemotherapy : No prior chemotherapy Endocrine therapy : No prior endocrine therapy Radiotherapy : No prior pelvic inguinal radiotherapy Surgery : See Disease Characteristics No prior definitive colostomy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>stage II anal cancer</keyword>
	<keyword>stage III anal cancer</keyword>
	<keyword>squamous cell carcinoma anus</keyword>
	<keyword>cloacogenic carcinoma anus</keyword>
	<keyword>basaloid carcinoma anus</keyword>
</DOC>